Key Highlights

  • Elevance Health (NYSE:ELV) reported third-quarter adjusted EPS of USD 6.99 on Wednesday, October 21, 2026, against the consensus estimate of USD 4.69, a gap of USD 2.30 per share.
  • The release says results include a net non-operating benefit of USD 1.85 per share, and net investment income rose 65.9% to USD 1.04 billion, a figure that stays inside adjusted EPS.
  • GAAP EPS was USD 6.27, with the USD 0.72 difference from adjusted EPS made up of amortisation, financial instrument losses, transaction costs and other items, net of tax.
  • Excluding the USD 1.85 benefit, adjusted EPS would have been about USD 5.14 on simple arithmetic, still above the USD 4.71 estimate flagged before results.

Bridging USD 4.69 to USD 6.99

Elevance Health (NYSE:ELV), a large US health insurer operating Anthem plans and the Carelon services businesses, reported third-quarter results before the open on Wednesday, October 21, 2026. Adjusted diluted EPS rose 15.9% to USD 6.99, against the consensus estimate of USD 4.69. GAAP diluted EPS rose 17.9% to USD 6.27. The two figures differ by USD 0.72 per share of adjustments: amortisation of USD 0.49, net losses on financial instruments of USD 0.22, transaction and integration costs of USD 0.19, business optimisation of USD 0.08 and litigation of USD 0.04, less a USD 0.31 tax effect. The release states that results include a net non-operating benefit of USD 1.85 per share. Net investment income rose to USD 1.04 billion from USD 625 million.

Why USD 6.99 Overstates the Run Rate

For Elevance Health (NYSE:ELV), most of the gap with consensus sits below the operating line. Adjusted EPS removes amortisation and one-off costs, but it keeps investment income, so the jump in net investment income flows into the USD 6.99. The company itself sets much of this aside: its 2027 baseline of at least USD 26.75 excludes non-recurring net investment income, other non-operating items and targeted one-time investments. Operating results were mixed. The benefit expense ratio, the share of premiums paid in claims, improved to 90.6% from 91.3%, yet Health Benefits operating gain fell 27.5% to USD 436 million as the operating expense ratio rose to 11.4%. CarelonRx and Carelon Services grew operating gain 10.8% and 33.3%.

Risks and What to Watch

The first risk for Elevance Health (NYSE:ELV) is that investors anchor on USD 6.99, when USD 1.85 of it came from a net non-operating benefit that the 2027 baseline treats as outside the run rate. The second is core insurance profitability, with the Health Benefits margin at 1.0% against 1.4% a year earlier. The third is membership: Medicare Advantage enrolment fell 15.5% to 1.90 million and Medicaid fell 4.9% to 8.22 million. Full-year GAAP adjustments also include a USD 4.28 per share accrual linked to a notice from the federal Medicare regulator. Investors should watch fourth-quarter adjusted EPS against an implied floor of about USD 1.94 on simple arithmetic and the USD 1.72 dividend, payable on Friday, December 18, 2026 to holders of record on Friday, December 4.

Where Things Stand

The answer is that a USD 1.85 per share non-operating benefit explains most of the USD 2.30 gap between adjusted EPS of USD 6.99 at Elevance Health (NYSE:ELV) and the USD 4.69 consensus estimate. The remainder, about USD 0.45 on simple arithmetic, reflected stronger underlying results, led by a lower benefit expense ratio and Carelon growth. The next catalysts are the dividend record date on December 4, its payment on December 18 and fourth-quarter results against the raised floor of at least USD 29.00. Guidance is a forecast, not a guarantee, and this is not investment advice.